Insights

Expanded Capabilities Samsung Biologics is expanding its biomanufacturing capacity with the launch of Bio Campus II, adding 180KL capacity by April 2025. This presents an opportunity for biopharmaceutical companies seeking CDMO partners with increased production capabilities.

Specialized Therapeutics Samsung Biologics is actively developing ADC drugs and antibody-drug conjugate therapeutics through collaborations, indicating a focus on specialized pharmaceutical products. Companies in need of expertise in this niche area can explore partnership opportunities with Samsung Biologics.

New Contract Development Platform The introduction of a new contract development platform by Samsung Biologics demonstrates a commitment to innovation and customized services. Businesses looking for tailored solutions in biologics development can leverage this platform for strategic partnerships.

Regulatory Approvals and Speed Samsung Biologics boasts proven regulatory approvals and the fastest throughput in the industry. This positions the company as a reliable and efficient partner for biopharmaceutical firms looking to expedite product development and market delivery timelines.

Technology Integration With a tech stack including Google Analytics, Red Hat, and more, Samsung Biologics emphasizes technology-driven operations. Companies seeking CDMO partners with advanced digital capabilities can benefit from synergistic collaborations with Samsung Biologics.

Similar companies to Samsung Biologics

Samsung Biologics Tech Stack

Samsung Biologics uses 8 technology products and services including Linkedin Ads, Google Analytics, GSAP, and more. Explore Samsung Biologics's tech stack below.

Linkedin Ads
Advertising
Google Analytics
Analytics
GSAP
Javascript Frameworks
Swiper
Javascript Libraries
Pardot
Marketing
Red Hat
Operating Systems
mod_jk
Web Server Extensions
Facebook
Widgets

Media & News

Samsung Biologics's Email Address Formats

Samsung Biologics uses at least 2 format(s):

Samsung Biologics Email Formats	Example	Percentage
first.last@samsung.com	John.Doe@samsung.com	44%
f.last@samsung.com	J.Doe@samsung.com	34%
first.l@samsung.com	John.D@samsung.com	10%
l.first@samsung.com	D.John@samsung.com	2%
last.f@samsung.com	Doe.J@samsung.com	2%
last.first@samsung.com	Doe.John@samsung.com	1%
fm.last@samsung.com	JM.Doe@samsung.com	1%
first@samsung.com	John@samsung.com	1%
flast@samsung.com	JDoe@samsung.com	1%
first.middle@samsung.com	John.Michael@samsung.com	0%
firstlast@samsung.com	JohnDoe@samsung.com	1%
filast@samsung.com	JoDoe@samsung.com	0%
lastf@samsung.com	DoeJ@samsung.com	1%
fmlast@samsung.com	JMDoe@samsung.com	0%
firstl@samsung.com	JohnD@samsung.com	0%
lastfi@samsung.com	DoeJo@samsung.com	0%
last@samsung.com	Doe@samsung.com	0%
firstmiddle.last@samsung.com	JohnMichael.Doe@samsung.com	1%
firlast@samsung.com	JohDoe@samsung.com	0%
firstlas@samsung.com	JohnDoe@samsung.com	0%
fir.last@samsung.com	Joh.Doe@samsung.com	0%
first_last@samsung.com	John_Doe@samsung.com	0%
lastfirst@samsung.com	DoeJohn@samsung.com	0%
middle@samsung.com	Michael@samsung.com	0%
first.m.last@samsung.com	John.M.Doe@samsung.com	1%
lastfir@samsung.com	DoeJoh@samsung.com	0%
lfirst@samsung.com	DJohn@samsung.com	0%
firstla@samsung.com	JohnDo@samsung.com	0%
first.middle.last@samsung.com	John.Michael.Doe@samsung.com	0%
first.middlelast@samsung.com	John.MichaelDoe@samsung.com	0%
first-last@samsung.com	John-Doe@samsung.com	0%
fimlast@samsung.com	JoMDoe@samsung.com	0%
firstmiddlelast@samsung.com	JohnMichaelDoe@samsung.com	0%
firstml@samsung.com	JohnMD@samsung.com	0%
firstmlast@samsung.com	JohnMDoe@samsung.com	0%
fmiddlelast@samsung.com	JMichaelDoe@samsung.com	0%
first_l@samsung.com	John_D@samsung.com	0%
f_last@samsung.com	J_Doe@samsung.com	0%
last_first@samsung.com	Doe_John@samsung.com	0%
firstmla@samsung.com	JohnMDo@samsung.com	0%
firstmiddlela@samsung.com	JohnMichaelDo@samsung.com	0%
firmlast@samsung.com	JohMDoe@samsung.com	0%
first-l@samsung.com	John-D@samsung.com	0%
firstmiddlelas@samsung.com	JohnMichaelDoe@samsung.com	0%
lf@samsung.com	DJ@samsung.com	0%
f-last@samsung.com	J-Doe@samsung.com	0%

Frequently Asked Questions

Where is Samsung Biologics's headquarters located?

Samsung Biologics's main headquarters is located at 300 Songdo Bio Way Yeonsu-gu, Incheon 21987 KR. The company has employees across 4 continents, including North AmericaEuropeAsia.

What is Samsung Biologics's official website and social media links?

Samsung Biologics's official website is samsungbiologics.com and has social profiles on LinkedIn.

How much revenue does Samsung Biologics generate?

As of May 2024, Samsung Biologics's annual revenue reached $750M.

What is Samsung Biologics's NAICS code?

Samsung Biologics's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Samsung Biologics have currently?

As of May 2024, Samsung Biologics has approximately 2.5K employees across 4 continents, including North AmericaEuropeAsia. Key team members include Chief Executive Officer: T. H. K.Chief Financial Officer: F. B.Chief Safety Officer: S. P.. Explore Samsung Biologics's employee directory with LeadIQ.

What industry does Samsung Biologics belong to?

Samsung Biologics operates in the Pharmaceutical Manufacturing industry.

What technology does Samsung Biologics use?

Samsung Biologics's tech stack includes Linkedin AdsGoogle AnalyticsGSAPSwiperPardotRed Hatmod_jkFacebook.

What is Samsung Biologics's email format?

Samsung Biologics's email format typically follows the pattern of . Find more Samsung Biologics email formats with LeadIQ.

When was Samsung Biologics founded?

Samsung Biologics was founded in 2011.

Samsung Biologics

Pharmaceutical ManufacturingIncheon, South Korea1001-5000 Employees

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.